Allergan Inc. Acknowledges Revised, Unsolicited Proposal From Valeant Pharmaceuticals International And Pershing Square

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today acknowledged that Valeant Pharmaceuticals International, Inc. (“Valeant”) and Pershing Square Capital Management, L.P. (“Pershing Square”) have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the “Re-Revised Proposal”).

Help employers find you! Check out all the jobs and post your resume.

Back to news